Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial-Reference-Cited by-同舟云学术

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial

Published:2022-05 Issue: Volume:166 Page:219-228
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Gelber Richard D.,Wang Xin V.,Cole Bernard F.^ORCID,Cameron David,Cardoso Fatima,Tjan-Heijnen Vivianne^ORCID,Krop Ian,Loi Sherene,Salgado Roberto,Kiermaier Astrid,Frank Elizabeth,Fumagalli Debora,Caballero Carmela^ORCID,de Azambuja Evandro,Procter Marion,Clark Emma,Restuccia Eleonora,Heeson Sarah,Bines Jose,Loibl Sibylle^ORCID,Piccart-Gebhart Martine

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference21 articles.

1. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer;von Minckwitz;N Engl J Med,2017

2. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

3. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data;Bonetti;Stat Med,2000

4. Patterns of treatment effects in subsets of patients in clinical trials

5. A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data;Bonetti;Stat Med,2009

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer;Breast Cancer Research;2024-02-07

2. Revolutionizing Breast Cancer Treatment: Unveiling the Effectiveness and Safety of Trastuzumab Deruxtecan through a Comprehensive Meta-Analysis;2024-02-07

3. Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial;JCO Precision Oncology;2024-02

4. Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023;Bulletin du Cancer;2023-11

5. Long-term prognostic benefit of adjuvant chemotherapy for patients with hepatoid adenocarcinoma of the stomach after radical resection: A national multicenter study;European Journal of Surgical Oncology;2023-11